CN1464049A - New polypeptide-human sailer transposase 11 and polynucleotides for coding same - Google Patents

Abstract

The present invention discloses one new kind of polypeptide, human sailor 11 transposase, polynucleotides encoding this polypeptide and recombination process to produce the polypeptide. The present invention also discloses the method of applying the polypeptide in treating various diseases, such as malignant tumor, ala-azar, etc. The present invention also discloses the agonist resisting the polypeptide and its treatment effect. The present invention also discloses the application of the polynucleotides encoding human sailor 11 transposase.

Description

A kind of new polypeptide-human sailor 11 transposases and the polynucleotide of this peptide species of coding

Technical field

The invention belongs to biological technical field, specifically, the invention describes a kind of new polypeptide-human sailor 11 transposases, and the polynucleotide sequence of this polypeptide of encoding.The invention still further relates to the preparation method and the application of these polynucleotide and polypeptide.

Background technology

Exist transferable controlling elements in the genome and in corn, find at first, in intestinal bacteria, insect, Mammals, also be found afterwards.Transposable element claims transposon again, is some dna sequence dnas, can shift between the perhaps same chromosomal different loci between homocellular coloured differently body.This transfer does not rely on the homology between the sequence, goes up this sequence in position and does not lose, and just its one new copy is inserted into new site.

The molecular structure of transposon has some common features: 1, most transposons comprise open reading frame (ORF), its transposase of may encoding.2, have inverted terminal repeat sequence (ITRs) at the two ends of transposon, they are most important in transposition.3, very short one section target sequence on the receptor dna, because the insertion of transposon, target sequence forms the forward tumor-necrosis factor glycoproteins in the both sides of transposon, the length of target sequence all is special to every class transposon.

In transposition on, transposase is necessary.Transposase also might be by other genes encoding by the open reading frame coding of transposon, and its effect is the transposition effect of catalysis transposon.

Inventor sailor's 11 transposases are a kind of new transposons---the transposase of people sailor's 11 transposons coding.People sailor's 11 transposons are a kind of of Mariner transposon, and the Mariner transposon belongs to transposable element mariner/Tc1 superfamily.Mariner transposon widely dispersed all has discovery in insect, nematode, flatworm and the Mammals genome of (comprising the people).The Mariner transposon is one of the simplest eukaryote transposon.Its feature is:. only comprise an open reading frame (ORF); The terminal repeat at its two ends (ITRs) approximately 30bp is long; The site of the DNA of identification is a TA dinucleotide sequence.

In the swivel base process, the Mariner transposon moves on the DNA intermediate with the mechanism of a kind of " shearing and stickup ", and the result is that transposon is cut out from the original place of DNA, and inserts genomic new location.The insertion target of Mariner transposon is one section TA dinucleotide sequence, and this section dinucleotide sequence is replicated when the Mariner transposon inserts.In the process of " shearing and stickup ", two key factors are arranged: the one, need transposase; The 2nd, inverted terminal repeat sequence (ITR) is arranged, transposase identification and mobile ITR in the transposon both sides.

The peculiar structural domain of transposase of this family's coding is " D, D35E " structure.This structural domain comprises that a conservative Asp links to each other with one section " D35E " zone." D35E " zone comprises conservative arginine and glutaminic acid residue, and 35 conservative relatively amino-acid residues are generally arranged in the middle of the two.

In vitro study shows that the Mariner transposon does not need other acting factors of cell just can carry out transposition independently, is autonomous therefore.And the transposition effect can be expressed and play to this transposon all in the cell of different genera.

Polypeptide of the present invention according to homology relatively can predicate new Mariner transposon.Discover that people sailor's 11 transposases and its polynucleotide of encoding are for medical diagnosis on disease, treatment, and cancer provides new constituent significant.

Summary of the invention

An object of the present invention is to provide isolating new polypeptide-human sailor 11 transposases with and fragment, analogue and derivative.

Another object of the present invention provides the polynucleotide of this polypeptide of coding.

Another object of the present invention provides the recombinant vectors of the polynucleotide that contain coding people sailor 11 transposases.

Another object of the present invention provides the genetically engineered host cell of the polynucleotide that contain coding people sailor 11 transposases.

Another object of the present invention provides the method for producing people sailor's 11 transposases.

Another object of the present invention provides the antibody at polypeptide-human sailor 11 transposases of the present invention.

Another object of the present invention has provided simulated compound, antagonist, agonist, the inhibitor at polypeptide-human sailor 11 transposases of the present invention.

Another object of the present invention provides the method for the diagnoses and treatment disease relevant unusually with people sailor's 11 transposases.

In a first aspect of the present invention, novel isolated people sailor 11 transposases are provided, this polypeptide is the people source, and it comprises: have＜polypeptide of 210〉2 aminoacid sequences or its conservative property variation polypeptide or its active fragments or its reactive derivative, analogue.Preferably, this polypeptide is to have＜polypeptide of 210〉2 aminoacid sequences.

In a second aspect of the present invention, the polynucleotide of isolating these polypeptide of coding are provided, these polynucleotide comprise a nucleotide sequence, and this nucleotide sequence is shown at least 76% homogeny with a kind of nucleotides sequence that is selected from down group: (a) polynucleotide of above-mentioned people sailor's 11 transposases of coding; (b) with polynucleotide (a) complementary polynucleotide.Preferably, this polynucleotide encoding have＜210〉2 shown in the polypeptide of aminoacid sequence.More preferably, the sequence of these polynucleotide is be selected from down group a kind of: (a) have＜210〉1 in the sequence of 127-441 position; (b) have＜210〉1 in the sequence of 1-1164 position.

In a third aspect of the present invention, the carrier that contains above-mentioned polynucleotide is provided, and has been transformed or host cell of transduceing or the host cell that is directly transformed or transduce by above-mentioned polynucleotide by this carrier.

Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.

As used herein, " isolating " are meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.

As used herein, " isolating people sailor's 11 transposases " are meant that people sailor's 11 transposases are substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can use purified technology of protein purifying people sailor 11 transposases of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.The purity of people sailor's 11 transposase polypeptide can be used amino acid sequence analysis.

The invention provides a kind of new polypeptide-human sailor 11 transposases, it is made up of the aminoacid sequence shown in the SEQ ID NO:2 basically.Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.

The present invention also comprises fragment, derivative and the analogue of people sailor's 11 transposases.As used herein, term " fragment ", " derivative " are meant biological function or the active polypeptide that keeps people sailor's 11 transposases of the present invention identical basically with " analogue ".The fragment of polypeptide of the present invention, derivative or analogue can be: (I) a kind of like this, wherein one or more amino-acid residues are replaced by conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the amino acid that replaces can be also can not encoded by genetic codon; Perhaps (II) is a kind of like this, and certain group on wherein one or more amino-acid residues is replaced by other group and comprises substituting group; Perhaps (III) is a kind of like this, and wherein mature polypeptide and another kind of compound (such as the compound that prolongs the polypeptide transformation period, for example polyoxyethylene glycol) merge; Perhaps (IV) is a kind of like this, wherein additional aminoacid sequence is integrated into mature polypeptide and the peptide sequence that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying) by the elaboration of this paper, such fragment, derivative and analogue are considered within those skilled in the art's ken.

The invention provides isolating nucleic acid (polynucleotide), substantially by coding have＜polynucleotide of the polypeptide of 210〉2 aminoacid sequences form.Polynucleotide sequence of the present invention comprises the nucleotide sequence of SEQ ID NO:1.Polynucleotide of the present invention are to find from the cDNA library of people's fetal brain tissue.The polynucleotide sequence total length that it comprises is 1164 bases, and its open reading frame (127---441) 104 amino acid of having encoded.Relatively find according to amino acid sequence homologous, this polypeptide and people Hsmarl have the { homology of 75%}, and this polypeptide has the peculiar structural domain of sailer transposase Zijia family, and deducibility goes out this new human sailer transposase and has the sailer transposase subbase because of the similar 26S Proteasome Structure and Function of family.

Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.The coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in＜210〉1 or the varient of degeneracy.As used herein, " varient of degeneracy " are meant that in the present invention coding has＜210〉2 protein or polypeptide, but with the differentiated nucleotide sequence of coding region sequence shown in＜210〉1.

The polynucleotide of the mature polypeptide of coding＜210〉2 comprise: the encoding sequence that has only mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.

Term " polynucleotide of coded polypeptide " is meant polynucleotide that comprise this polypeptide of encoding and the polynucleotide that comprise additional code and/or non-coding sequence.

The invention still further relates to the varient of foregoing description polynucleotide, its coding has the polypeptide of identical aminoacid sequence or segment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.

The invention still further relates to and the polynucleotide (have at least 50% between two sequences, preferably have 70% homogeny) of sequence hybridization described above.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time adds and to use denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function and activity with the mature polypeptide shown in the SEQ ID NO:2.

The invention still further relates to nucleic acid fragment with sequence hybridization described above.As used herein, " nucleic acid fragment " length contain 10 Nucleotide at least, better be 20-30 Nucleotide at least, be more preferably 50-60 Nucleotide at least, preferably more than at least 100 Nucleotide.Nucleic acid fragment also can be used for the amplification technique (as PCR) of nucleic acid to determine and/or to separate the polynucleotide of coding people sailor 11 transposases.

Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.

The special polynucleotide sequence of coding people sailor 11 transposases of the present invention can obtain with several different methods.For example, separate polynucleotide with hybridization technique well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homologous polynucleotide sequence and 2) antibody screening of expression library to be to detect the polynucleotide passage of the clone with common structure feature.

Sequence dna fragment of the present invention also can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of described polypeptide.

In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.The direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.The more frequent method of selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., MolecularCloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.

Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) appearance of marker gene function or forfeiture; (3) level of the transcript of mensuration people sailor 11 transposases; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.

In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 10 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, within 2000 Nucleotide, preferable is within 1000 Nucleotide to the length of probe usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene order information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.

In (4) kind method, detect people sailor's 11 transposase gene expressed proteins products and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc.

Use method (Saiki, the et al.Science1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to from the library, obtain the cDNA of total length, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to polynucleotide sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.

The gene of the present invention that obtains as mentioned above, perhaps the polynucleotide sequence of various dna fragmentations etc. can with ordinary method such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467) measure.This class polynucleotide sequence is measured also available commercial sequencing kit etc.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.

The present invention also relates to comprise the carrier of polynucleotide of the present invention, and the host cell that produces through genetically engineered with the carrier of the present invention or the sailor's 11 transposase encoding sequences of directly choosing, and the method that produces polypeptide of the present invention through recombinant technology.

Among the present invention, the polynucleotide sequence of coding people sailor 11 transposases can be inserted in the carrier, contains the recombinant vectors of polynucleotide of the present invention with formation.Term " carrier " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carrier.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on the T7 promotor of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier may be used to make up recombinant expression vector.A key character of expression vector is to contain replication origin, promotor, marker gene and translational control element usually.

Method well-known to those having ordinary skill in the art can be used to make up the dna sequence dna that contains coding people sailor 11 transposases and the expression vector of suitable transcribing/translational control element.These methods comprise (Sambroook, et al.Molecular Cloning, a LaboratoryManual, cold Spring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; The P of lambda particles phage _LPromotor; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in prokaryotic cell prokaryocyte or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site that translation initiation is used and transcription terminator etc.Inserting enhancer sequence in carrier will make its transcribing in higher eucaryotic cells be enhanced.Enhanser is the cis acting factor that DNA expresses, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.

In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance etc.

Persons skilled in the art all know how to select appropriate carriers/transcriptional regulatory element (as promotor, enhanser etc.) and selected marker.

Among the present invention, the polynucleotide of coding people sailor 11 transposases or the recombinant vectors that contains these polynucleotide can transform or transduce into host cell, contain the genetically engineered host cell of these polynucleotide or recombinant vectors with formation.Term " host cell " refers to prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; Bacterial cell such as Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; Insect cell such as fruit bat S2 or Sf9; Zooblast such as CHO, COS or Bowes melanoma cells etc.

Can carry out with routine techniques well known to those skilled in the art with dna sequence dna of the present invention or the recombinant vectors transformed host cell that contains described dna sequence dna.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results ₂Method is handled, and used step is well-known in this area.Alternative is to use MgCl ₂If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, perhaps conventional mechanical method such as microinjection, electroporation, liposome packing etc.

By the recombinant DNA technology of routine, utilize polynucleotide sequence of the present invention to can be used to express or produce people sailor's 11 transposases (Science, 1984 of reorganization; 224:1431).In general following steps are arranged:

(1). with the polynucleotide (or varient) of everybody sailor's 11 transposases of coding of the present invention, or transform or the transduction proper host cell with the recombinant expression vector that contains these polynucleotide;

(2). in suitable medium, cultivate host cell;

(3). separation, protein purification from substratum or cell.

In step (2), according to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.

In step (3), recombinant polypeptide can wrap and be expressed or be secreted into the extracellular in cell or on cytolemma.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.These methods include, but are not limited to: conventional renaturation is handled, protein precipitant is handled (salt analysis method), centrifugal, the broken bacterium of infiltration, the combination of ultrasonication, super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.

The antagonist of polypeptide of the present invention and this polypeptide, agonist and inhibitor can be directly used in disease treatment, for example, can treat malignant tumour, kala-azar etc.

People sailor's 11 transposase albumen or polypeptide are of use in many ways.These purposes include, but is not limited to directly as the disease due to pharmacological agent people sailor 11 transposase hypofunctions or the forfeiture and are used to screen promote or antibody, polypeptide or other part of antagonism people sailor 11 transposase functions.For example, antibody can be used for activating or suppressing the function of people sailor's 11 transposases.The peptide molecule that can suppress or stimulate people sailor's 11 transposase functions that can be used for seeking therapeutic value with recombinant human sailor's 11 transposase protein screening peptide libraries of expressing.

People sailor's 11 transposons can be used as carrier goal gene are imported in the dissimilar zooblasts.In vitro study shows that transposase does not need other acting factors of cell just can carry out transposition independently, and this characteristic has shown its potentiality in study of disease mechanism and gene therapy.For example: also do not have to find a kind of gratifying vaccine or chemotherapy to treat leishmaniasis Leishmania major (kala-azar) till now, a kind of lethal propagation is tropical disease widely.If people sailor's 11 transposons are introduced in the genome of pathogenic agent---large-scale crithidia cunninghami---of kala-azar, just might study the pathogeny of kala-azar.For those because genetic flaw or disappearance can not give expression to protein with normal function and morbific disease; can utilize people sailor's 11 transposons that normal gene is imported target cell, stably express goes out normal albumen and makes disease be alleviated or cure.

The antagonist of people sailor's 11 transposases or fragment or derivative can be used to treatment or preventing cancer, and cancer comprises but (being not limited to) gland cancer, leukemia, lymphoma, melanoma, sarcoma, myelomatosis, teratoma etc.; Especially adrenal carcinoma, bladder cancer, osteocarcinoma, bone marrow cancer, the cancer of the brain, mammary cancer, uterus carcinoma, carcinoma of gallbladder, nervous center cancer, kidney, liver cancer, lung cancer, thyroid carcinoma, thymic carcinoma etc.Can directly be used as antagonist with people sailor's 11 transposase specificity bonded antibody, or with target or pass through mechanism medicament be taken in the cell or tissue of expressing human sailer transposase enzyme indirectly.The antagonist of people sailor's 11 transposases or fragment or derivative can be used to treatment or preventing cancer immunologic derangement.

The present invention also provides SCREENED COMPOUND to identify the method that improves (agonist) or check the medicament of (antagonist) people sailor 11 transposases.Agonist improves people sailor's 11 transposases biological function such as stimulate cellular proliferation, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.For example, can in the presence of medicine, the film preparation of mammalian cell or expressing human sailor 11 transposases be cultivated with people sailor's 11 transposases of mark.Measure the medicine raising then or check this interactional ability.

The antagonist of people sailor's 11 transposases comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.The antagonist of people sailor's 11 transposases can combine and eliminate its function with people sailor's 11 transposases, or suppresses the generation of this polypeptide, or combines with the avtive spot of this polypeptide and to make this polypeptide can not bring into play biological function.

In screening during as the compound of antagonist, people sailor's 11 transposases can be added during bioanalysis measures, determine to interactional influence between people sailor's 11 transposases and its acceptor whether compound is antagonist by measuring compound.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with people sailor's 11 transposase bonded peptide molecules obtains.During screening, generally tackle people sailor's 11 transposase molecules and carry out mark.

The invention provides and use polypeptide, and fragment, derivative, analogue or their cell are as the method for antigen with production antibody.These antibody can be polyclonal antibody or monoclonal antibody.The present invention also provides the antibody at people sailor 11 transposase antigenic determinants.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.

Can the choose method of sailor 11 transposase direct injection immune animals (as rabbit, mouse, rat etc.) of the production of polyclonal antibody obtains, and multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.The technology of the monoclonal antibody of preparation people sailor 11 transposases include but not limited to hybridoma technology (Kohler andMilstein.Nature, 1975,256:495-497), three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.Pat No.4946778) also can be used for producing the single-chain antibody of anti-people sailor's 11 transposases.

The antibody of anti-people sailor's 11 transposases can be used in the immunohistochemistry technology, detects people sailor's 11 transposases in the biopsy specimen.

With the also available labelled with radioisotope of people sailor's 11 transposase bonded monoclonal antibodies, inject in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.

Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As the monoclonal antibody of people sailor's 11 transposase high-affinities can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing people sailor's 11 transposase positive cells.

Antibody among the present invention can be used for treating or prevention and the relevant disease of people sailor's 11 transposases.The antibody that gives suitable dosage can stimulate or block the generation or the activity of people sailor's 11 transposases.

The invention still further relates to the diagnostic testing process of quantitative and detection and localization people sailor 11 transposase levels.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.The people sailor's 11 transposase levels that detected in the test can be with laying down a definition the importance of people sailor's 11 transposases in various diseases and be used to the disease of diagnosing people sailor's 11 transposases to work.

Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carries out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension, be more preferably and carry out mass spectroscopy.

The polynucleotide of coding people sailor 11 transposases also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating because cell proliferation, growth or the metabolic disturbance due to the nothing expression of people sailor's 11 transposases or the unusual/non-activity expression.The gene therapy vector (as virus vector) of reorganization can be designed for people sailor's 11 transposases of expressing variation, to suppress endogenic people sailor's 11 transposase activity.For example, a kind of people sailor's 11 transposases of variation can be people sailor's 11 transposases that shorten, lacked signal conduction function territory, though can combine with the substrate in downstream, lack signaling activity.Therefore the gene therapy vector of reorganization can be used for treating the disease of expression of people sailor's 11 transposases or active caused by abnormal.Deriving from viral expression vector such as retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for the polynucleotide of coding people sailor 11 transposases are transferred in the cell.The method of recombinant viral vector that structure carries the polynucleotide of coding people sailor 11 transposases is found in existing document (Sambrook, et al.).The polynucleotide of reorganization coding people sailor 11 transposases can be packaged in the liposome and be transferred in the cell in addition.

Polynucleotide import tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.

Suppress the oligonucleotide (comprising sense-rna and DNA) of people sailor 11 transposase mRNA and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.

The polynucleotide of coding people sailor 11 transposases can be used for the diagnosis with the relative disease of people sailor's 11 transposases.The unconventionality expression of the expression that the polynucleotide of coding people sailor 11 transposases can be used for detecting people sailor's 11 transposases people sailor's 11 transposases whether or under morbid state.As the dna sequence dna of people sailor's 11 transposases of encoding can be used for biopsy specimen is hybridized to judge the expression situation of people sailor's 11 transposases.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.The special primer of personnel selection sailor's 11 transposases carries out the transcription product that RNA-polymerase chain reaction (RT-PCR) amplification in vitro also can detect people sailor's 11 transposases.

The sudden change that detects people sailor's 11 transposase genes also can be used for the disease of diagnosing people sailor's 11 transposases relevant.The form of people sailor's 11 transposases sudden changes comprises that the point mutation compared with normal wild type people sailor 11 transposase dna sequences, transposition, disappearance, reorganization and other are any unusual etc.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.

Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.

In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.

The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).

The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manualof Basic Techniques, Pergamon Press, New York (1988).

In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, MendelianInheritance in Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.

Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.Resolving power according to present physical mapping and assignment of genes gene mapping technology, being accurately positioned to the cDNA of the chromosomal region relevant with disease, can be a kind of (the supposing that 1 megabasse mapping resolving power and every 20kb are corresponding to a gene) between 50 to 500 potential Disease-causing genes.

Polypeptide of the present invention, polynucleotide and stand-in thereof, agonist, antagonist and inhibitor and suitable pharmaceutical carrier combination back can be used.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.

The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.

Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.People sailor's 11 transposases come administration with the amount that treats and/or prevents concrete indication effectively.The amount and the dosage range that are applied to people sailor's 11 transposases of patient will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.

Description of drawings

Following accompanying drawing is used to illustrate specific embodiments of the present invention, and is not used in qualification by the scope of the invention that claims defined.

Fig. 1 is the amino acid sequence homology comparison diagram of inventor sailor's 11 transposases and people Hsmarl.The top sequence is people sailor's 11 transposases, and the below sequence is people Hsmarl.Same amino acid represents with monocase amino acid that between two sequences similar amino acid is represented with "+".

Fig. 2 is the polyacrylamide gel electrophoresis figure (SDS-PAGE) of isolating people sailor's 11 transposases.11.5kDa be proteinic molecular weight.The arrow indication is isolated protein band.

Embodiment

Embodiment 1: the clone of people sailor 11 transposase cDNA

Extract the total RNA of people's tire brain with guanidinium isothiocyanate/phenol/chloroform single stage method.From total RNA, separate poly (A) mRNA with Quik mRNA Isolation Kit (Qiegene company product).2ug poly (A) mRNA forms cDNA through reverse transcription.Clone test kit (available from Clontech) with SmartcDNA and cDNA fragment orientation is inserted on the multiple clone site of pBSK (+) carrier (Clontech company product), transform DH5 α bacterium and form the cDNA library.Measure all clones' 5 ' and 3 ' terminal sequence with Dyeterminate cycle reaction sequencingkit (Perkin-Eimer company product) and ABI 377 automatic sequencings views (Perkin-Elmer company).CDNA sequence and the existing public dna sequence data storehouse (Genebank) measured are compared, and the cDNA sequence that found that one of them clone (0509d01) is new DNA.By synthetic a series of primers the contained insertion cDNA fragment of this clone is carried out two-way mensuration.The result shows, the contained full-length cDNA of 0509d01 clone is 1164bp (as＜210〉1 shown in), from 127bp to 441bp the open reading frame (ORF) of a 104bp, the new protein (shown in Seq ID NO:2) of encoding arranged.We are with this clone's called after pBS-0490B02, and the name of encoded protein matter is people sailor's 11 transposases.

Embodiment 2:cDNA clone's homology retrieval

With the sequence and the encoded protein sequence thereof of people sailor's 11 transposase genes of the present invention, with Blast program (Basiclocal Alignment search tool) [Altschul, SF et al.J.Mol.Biol.1990; 215:403-10], carry out the homology retrieval at databases such as Genbank, Swissport.The gene the highest with people sailor's 11 transposase gene homologys of the present invention is a kind of known people Hsmar1 gene, and its encoded protein number is U52077 in the access of Genbank.Protein homology the results are shown in Fig. 1, both height homologies, and its homogeny is 75%; Similarity is 81%.

Embodiment 3: with RT-PCR method human cloning sailor 11 transposase genes

Total RNA is a template with fetus brain cell, is that primer carries out the synthetic cDNA of reverse transcription reaction with oligo-dT, with behind the test kit purifying of Qiagene, carries out pcr amplification with following primer:

Primer1：5’-ACACAAGCGCTTCCTTGCCGAG-3’ (<210>3)

Primer2:5 '-CTCAAACACATCTTTATTCATC-3 ' (＜210〉4) Primer1 is the forward sequence that begins of 1bp that is positioned at the 5 ' end of SEQ ID NO1; Primer2 be＜210〉1 in 3 ' end reverse sequence.The condition of amplified reaction: in the reaction volume of 50 μ l, contain 50mmol/L KCl, 10mmol/LTris-Cl, (pH8.5), 1.5mmol/LMgCl2,200 μ mol/L dNTP, 10pmol primer, the TaqDNA polysaccharase of 1U (Clontech company product).Go up by 25 cycles of following conditioned response at PE9600 type DNA thermal cycler (Perkin-Elmer company): 94 ℃, 30sec; 55 ℃, 30sec; 72 ℃, 2min.When RT-PCR, establish the blank negative contrast of positive contrast of β-actin and template simultaneously.Amplified production is connected to (Invitrogen company product) on the pCR carrier with the test kit purifying of QIAGEN company with TA clone test kit.The dna sequence analysis result shows the dna sequence dna and＜210 of PCR product〉1-1164bp shown in 1 is identical.

The expression of embodiment 4:Northern blotting analyst sailor 11 transposase genes:

Extract total RNA[Anal.Biochem 1987,162,156-159 with single stage method].This method comprises acid guanidine thiocyanate phenol-chloroform extracting.Promptly use 4M guanidinium isothiocyanate-25mM Trisodium Citrate, 0.2M sodium acetate (pH4.0) advances ground homogenate to tissue, adds the phenol of 1 times of volume and the chloroform-primary isoamyl alcohol (49: 1) of 1/5 volume, and is centrifugal after mixing.The sucking-off aqueous phase layer adds Virahol (0.8 volume) and with the centrifugal RNA precipitation that obtains of mixture.With RNA precipitation 70% washing with alcohol that obtains, dry and soluble in water.With 20 μ g RNA, on 1.2% sepharose that contains 20mM3-(N-morpholino) propanesulfonic acid (pH7.0)-5mM sodium acetate-1mMEDTA-2.2M formaldehyde, carry out electrophoresis.Be transferred on the nitrocellulose filter then.With α- ³²PdATP prepares by random priming ³²The dna probe of P-mark.Used dna probe is the HRBP-3 coding region sequence (127bp to 441bp) of pcr amplification shown in Figure 1.Will ³²The probe of P-mark (about 2 * 10 ⁶Pm/ml) spend the night in 42 ℃ of hybridization in a solution with the nitrocellulose filter that has shifted RNA, this solution comprises 50% methane amide-25mMKH2PO4 (pH7.4)-5 * SSC-5 * Denhardt ' s solution and 200 μ g/ml salmon sperm DNAs.After the hybridization, filter membrane is washed 30min in 55 ℃ in 1 * SSC-0.1%SDS.Then, analyze with quantitative with Phosphor Imager.

Example 5: vivoexpression, separation and the purifying of recombinant human sailor's 11 transposases

According to＜210〉1 and coding region sequence shown in Figure 1, design a pair of specificity amplification primer, sequence is as follows:

Primer?3：5’-CCCCCATGGATGGAAATGATGTTAGACAAA-3’ (<210>5)

5 ' end of these two sections primers of Primer4:5 '-CCCGGATCCTCAAATGCTGAATGACCGTAG-3 ' (＜210〉6) contains NcoI and BamHI restriction enzyme site respectively, be respectively the encoding sequence of target gene 5 end and 3 ' end thereafter, NcoI and BamHI restriction enzyme site are corresponding to expression vector plasmid pET-28b (+) (Novagen company product, Cat.No.69865.3) the selectivity restriction enzyme site on.With the pBS-0509d01 plasmid that contains the total length goal gene is template, carries out the PCR reaction.The PCR reaction conditions is: contain pBS-0509d01 plasmid 10pg, primer Primer-3 and Primer-4 among the cumulative volume 50 μ l and be respectively 10pmmol, Advantage polymerase Mix (Clontech company product) 1 μ l.Loop parameter: 94 ℃, 20s, 60 ℃ of 30s, 68 ℃ of 2min, totally 25 circulations.Respectively amplified production and plasmid pET-28 (+) are carried out double digestion with NcoI and BamHI, reclaim big fragment respectively, and connect with the T4 ligase enzyme.Connect product and transform, after the dull and stereotyped overnight incubation of the LB that contains kantlex (final concentration 30 μ g/ml), use the colony polymerase chain reaction (PCR) method screening positive clone, and check order with the big enterobacterial Dh5 of Calcium Chloride Method α.Select the correct positive colony of sequence (pET-0509d01) with Calcium Chloride Method with recombinant plasmid transformed large intestine bar BL21 (DE3) plySs (Novagen company product).In the LB liquid nutrient medium that contains kantlex (final concentration 30 μ g/ml), host bacterium BL21 (pET-0509d01) is cultured to logarithmic phase at 37 ℃, adds IPTG to final concentration 1mmol/L, continues to cultivate 5 hours.Centrifugal collection thalline, through the broken bacterium of ultrasonic wave, centrifugal collection supernatant with carrying out chromatography with 6 Histidines (6His-Tag) bonded affinity column His.Bind QuickCartidge (Novagen company product), has obtained target protein people sailor 11 transposases of purifying.Through the SDS-PAGE electrophoresis, obtain a single band (Fig. 2) at the 11.5kDa place.This band is transferred on the pvdf membrane carries out the n terminal amino acid sequential analysis with the Edams hydrolysis method, 15 amino acid of N-end are identical with 15 amino-acid residues of N-end shown in＜210〉2 as a result.

Embodiment 6: anti-people sailor's 11 transposase production of antibodies

Synthesize the specific polypeptide of following people sailor's 11 transposases with Peptide synthesizer (PE company product): NH2-Met-Glu-Met-Met-Leu-Asp-Lys-Lys-Gln-Ile-Gln-Val-Ile-Phe-Leu-COOH

Form compoundly with hemocyanin and bovine serum albumin coupling this polypeptide respectively, method is referring to Avrameas, etal.Immunochemistry, 1969; 6:43.Add the complete Freund's adjuvant immunizing rabbit with the above-mentioned hemocyanin polypeptide complex of 4mg, add the incomplete Freund's adjuvant booster immunization once with the hemocyanin polypeptide complex again after 15 days.Employing is done the titre that ELISA measures antibody in the rabbit anteserum through the titer plate of 15 μ g/ml bovine serum albumin polypeptide complex bag quilts.From the rabbit anteserum of antibody positive, separate total IgG with albumin A-Sepharose.Polypeptide is incorporated on the Sepharose4B post of cyanogen bromide-activated, from total IgG, separates anti-peptide antibody with affinity chromatography.Immuno-precipitation proof antibody purified can combine with people sailor's 11 transposases specifically.

Sequence table＜110〉Bode Gene Development Co., Ltd., Shanghai＜120〉polynucleotides＜130〉0509d01＜160〉6＜170〉PatentIn version 3.1＜210 of a kind of new polypeptide one people sailor 11 transposases and this peptide species of coding〉1＜211〉1164＜212〉DNA＜213〉Homo sapiens＜220〉＜221〉CDS＜222〉(127) .. (441)＜223〉＜400〉1acacaagcgc ttccttgccg agaggctgga gctgcggcac cgcaggcctg agccacccct 60tctctgctgt ctccttctct tcctcagggc tcccgtgtct gctcgccctc cgacgctgct 120cagact atg gaa atg atg tta gac aaa aag caa att caa gtg att ttc 168

Met?Glu?Met?Met?Leu?Asp?Lys?Lys?Gln?Ile?Gln?Val?Ile?Phe

1 5 10tta?ttc?aag?ttc?aaa?atg?ggt?cat?aaa?gca?gca?gag?aca?act?cgc?agc 216Leu?Phe?Lys?Phe?Lys?Met?Gly?His?Lys?Ala?Ala?Glu?Thr?Thr?Arg?Ser15 20 25 30atc?aac?aat?gca?ttt?ggc?cca?gaa?att?gct?aac?aaa?ggt?aca?gtg?cag 264Ile?Asn?Asn?Ala?Phe?Gly?Pro?Glu?Ile?Ala?Asn?Lys?Gly?Thr?Val?Gln

35 40 45tgg?tgg?ttc?aag?aac?ttt?tgc?aaa?gga?gac?gag?agc?cgt?gaa?gat?gag 312Trp?Trp?Phe?Lys?Asn?Phe?Cys?Lys?Gly?Asp?Glu?Ser?Arg?Glu?Asp?Glu

50 55 60gag?tgt?tgt?gcc?cgg?cca?tca?aaa?gtt?ggc?aac?gac?caa?ttg?aga?gca 360Glu?Cys?Cys?Ala?Arg?Pro?Ser?Lys?Val?Gly?Asn?Asp?Gln?Leu?Arg?Ala

65 70 75atc?atc?gaa?gct?gat?cct?ctt?aca?aca?cta?gaa?gtt?gcc?gag?aac?tca 408Ile?Ile?Glu?Ala?Asp?Pro?Leu?Thr?Thr?Leu?Glu?Val?Ala?Glu?Asn?Ser

80 85 90aca?tca?acc?atc?cta?cgg?tca?ttc?agc?att?tga?agcaaattag?aaggttgtaa 461Thr?Ser?Thr?Ile?Leu?Arg?Ser?Phe?Ser?Ile95 100aagctcgata?agtgggtgcc?tcatgagctg?actgaaaata?aaaacaatcg?tcattttgaa 521gtgttgtctt?ctcttacttt?gtgtaacaac?aatgaaccat?ttcttgatca?gattgtgacg 581tgcgttggta?agtggatttt?atatgacaac?cgctgatgac?cagcttggtg?gttggactga 641gaagaagctc?cagagcactt?cccaaagcca?aacttctacc?aaaatgttaa?tggtcactgt 701ttgatggtct?gctgccggtc?tgatccacta?cagctttctg?agttccagca?aaaccattac 761atctgagaag?tatgctcaac?aaatctctga?gatgcatgga?aagctgcaac?gcctgcagcc 821agcattgatc?aacataaagg?gcccagtcct?tcggcacaac?aatgcctgac?aatgcgtcgc 881acaaccaacg?cttcaaaagt?tgaatgaatt?gggcacaaag?ttttgcctca?tccaccgtat 941tcacctgact?tcttgccaac?tgactaccac?ttcttcaagc?atctcagcaa?ctttttgcag 1001ggaagatgtt?tccacaacca?gaatgcagaa?aaagctttcc?aagagtttat?cgaatcccag 1061atcacacatt?tttacactac?aggaataaat?aaacttattt?ctcattggca?aaaatgtgtt 1121gattgtaatg?tttcctattt?tgatgaataa?agatgtgttt?gag1164<210>2<211>104<212>PRT<213>Homo?sapiens<400>2Met?Glu?Met?Met?Leu?Asp?Lys?Lys?Gln?Ile?Gln?Val?Ile?Phe?Leu?Phe1 5 10 15Lys?Phe?Lys?Met?Gly?His?Lys?Ala?Ala?Glu?Thr?Thr?Arg?Ser?Ile?Asn

20 25 30Asn?Ala?Phe?Gly?Pro?Glu?Ile?Ala?Asn?Lys?Gly?Thr?Val?Gln?Trp?Trp

35 40 45Phe?Lys?Asn?Phe?Cys?Lys?Gly?Asp?Glu?Ser?Arg?Glu?Asp?Glu?Glu?Cys

50 55 60Cys?Ala?Arg?Pro?Ser?Lys?Val?Gly?Asn?Asp?Gln?Leu?Arg?Ala?Ile?Ile65 70 75 80Glu?Ala?Asp?Pro?Leu?Thr?Thr?Leu?Glu?Val?Ala?Glu?Asn?Ser?Thr?Ser

85 90 95Thr?Ile?Leu?Arg?Ser?Phe?Ser?Ile

100<210>3<211>22<212>DNA<213>Homo?sapiens<400>3acacaagcgc?ttccttgccg?ag22<210>4<211>22<212>DNA<213>Homo?sapiens<400>4ctcaaacaca?tctttattca?tc22<210>5<211>30<212>DNA<213>Homo?sapiens<400>5cccccatgga?tggaaatgat?gttagacaaa30<210>6<211>30<212>DNA<213>Homo?sapiens<400>6cccggatcct?caaatgctga?atgaccgtag30

Claims (18)

1, a kind of isolated polypeptide-people sailor's 11 transposases is characterized in that it includes: the polypeptide of the aminoacid sequence shown in＜210〉2 or the active fragments of its polypeptide, analogue or derivative.

2, polypeptide as claimed in claim 1, the aminoacid sequence that it is characterized in that described polypeptide, analogue or derivative has the homogeny with the aminoacid sequence at least 95% shown in＜210〉2.

3, polypeptide as claimed in claim 2 is characterized in that it comprises and has＜polypeptide of the aminoacid sequence shown in 210〉2.

4, a kind of isolating polynucleotide, it is characterized in that described polynucleotide comprise be selected from down the group in a kind of:

(a) coding have＜210〉2 shown in the polynucleotide of the polypeptide of aminoacid sequence or its fragment, analogue, derivative;

(b) with polynucleotide (a) complementary polynucleotide; Or

(c) with (a) or the polynucleotide of at least 76% homogeny (b) are arranged.

5, polynucleotide as claimed in claim 4, it is characterized in that described polynucleotide comprise coding and have＜210〉2 shown in the polynucleotide of aminoacid sequence.

6, polynucleotide as claimed in claim 4, it is characterized in that the sequence of described polynucleotide includes＜210〉1 in the 127-441 position sequence or＜210〉1 in the sequence of 1-1164 position.

7, a kind of recombinant vectors that contains exogenous polynucleotide is characterized in that it is the recombinant vectors that is formed by the described polynucleotide of arbitrary claim among the claim 4-6 and plasmid, virus or vehicle expression vector establishment.

8, a kind of genetically engineered host cell that contains exogenous polynucleotide is characterized in that it is to be selected from following a kind of host cell:

(a) host cell that transforms or transduce with the described recombinant vectors of claim 7; Or

(b) host cell that transforms or transduce with the described polynucleotide of the arbitrary claim among the claim 4-6.

9, a kind of preparation method with the active polypeptide of people sailor's 11 transposases is characterized in that described method comprises:

(a) under expressing human sailor 11 transposase conditions, cultivate the described through engineering approaches host cell of claim 8;

(b) from culture, isolate and have the active polypeptide of people sailor's 11 transposases.

10, a kind of can with polypeptide bonded antibody, it is characterized in that described antibody be can with people sailor's 11 transposase specificity bonded antibody.

11, the compound of an analoglike or adjusting polypeptide active or expression is characterized in that they are simulation, promotion, antagonism or the active compound that suppresses people sailor's 11 transposases.

12, compound as claimed in claim 11 is characterized in that it is＜polynucleotide sequence or its segmental antisense sequences shown in 210〉1.

13, the described application of compound of a kind of claim 11, it is characterized in that described compound be used for mediator sailor's 11 transposases in vivo, the method for external activity.

14, a kind of disease relevant or method of disease susceptibility of detecting with the described polypeptide of arbitrary claim among the claim 1-3, it is characterized in that it comprises the described polypeptide expression amount that detects, perhaps detect the activity of described polypeptide, perhaps detect and cause described expression of polypeptides amount or active unusual nucleotide diversity in the polynucleotide.

15, as the application of polypeptide as described in the arbitrary claim among the claim 1-3, it is characterized in that it is applied to screen the stand-in of people sailor's 11 transposases, agonist, antagonist or inhibitor; Perhaps be used for the peptide finger print identification.

16, as the application of the described nucleic acid molecule of arbitrary claim among the claim 4-6, it is characterized in that it is used for nucleic acid amplification reaction as primer, perhaps be used for hybridization, perhaps be used to make gene chip or microarray as probe.

17,, it is characterized in that forming pharmaceutical composition with safe and effective dosage and pharmaceutically acceptable carrier as diagnosis or the treatment disease relevant unusually with people sailor's 11 transposases with described polypeptide, polynucleotide or its stand-in, agonist, antagonist or inhibitor as the described polypeptide of arbitrary claim, polynucleotide or application of compound in claim 1-6 and 11.

18, the described polypeptide of arbitrary claim, polynucleotide or the application of compound among the claim 1-6 and 11 is characterized in that being used for the treatment of as malignant tumour with described polypeptide, polynucleotide or compound the medicine of kala-azar.

Images